Results 1 to 10 of about 865,522 (266)

A comparison of the binding sites of antibodies and single-domain antibodies [PDF]

Frontiers in Immunology, 2023
Antibodies are the largest class of biotherapeutics. However, in recent years, single-domain antibodies have gained traction due to their smaller size and comparable binding affinity.
Gemma L. Gordon, Henriette L. Capel, Bora Guloglu, Eve Richardson, Ryan L. Stafford, Charlotte M. Deane   +5 more
doaj   +4 more sources

Single-domain antibodies as therapeutics for solid tumor treatment [PDF]

Acta Pharmaceutica Sinica B
Single-domain antibodies (sdAbs), initially identified in camelids or sharks and commonly referred to as nanobodies or VNARs, have emerged as a promising alternative to conventional therapeutic antibodies.
Mingkai Wang, Tianlei Ying, Yanling Wu
doaj   +3 more sources

Humanized single domain antibodies neutralize SARS-CoV-2 by targeting the spike receptor binding domain

Nature Communications, 2020
Here, using a humanized phage display library with recombinant SARS- CoV-2 receptor binding domain (RBD) proteins, the authors identify a number of single domain antibodies (sdAbs) that neutralize SARS-CoV-2 in vitro by inhibiting the interaction of the ...
Xiaojing Chi, Xiuying Liu, Conghui Wang, Xinhui Zhang, Xiang Li, Jianhua Hou, Lili Ren, Qi Jin, Jianwei Wang, Wei Yang   +9 more
doaj   +2 more sources

Transportation of Single-Domain Antibodies through the Blood–Brain Barrier

Biomolecules, 2021
Single-domain antibodies derive from the heavy-chain-only antibodies of Camelidae (camel, dromedary, llama, alpaca, vicuñas, and guananos; i.e., nanobodies) and cartilaginous fishes (i.e., VNARs).
Eduardo Ruiz-López, Alberto J. Schuhmacher   +1 more
doaj   +2 more sources

Targeting the Brain with Single-Domain Antibodies: Greater Potential Than Stated So Far? [PDF]

Int J Mol Sci, 2023
Treatments for central nervous system diseases with therapeutic antibodies have been increasingly investigated over the last decades, leading to some approved monoclonal antibodies for brain disease therapies.
Tsitokana ME, Lafon PA, Prézeau L, Pin JP, Rondard P.   +4 more
europepmc   +2 more sources

Species-Dependent Structural Variations in Single-Domain Antibodies [PDF]

Antibodies
Background/Objectives: Single-domain antibodies (sdAbs) are derived from camelid heavy-chain antibodies (HCAb). Their small size, high stability, and ease of production, among other properties, makes them highly valuable in biomedical research and ...
Marta Baselga, Javier Sánchez-Prieto, Víctor Manuel Medina Pérez, Alberto J. Schuhmacher   +3 more
doaj   +2 more sources

Brain Delivery of Single-Domain Antibodies: A Focus on VHH and VNAR

Pharmaceutics, 2020
Passive immunotherapy, i.e., treatment with therapeutic antibodies, has been increasingly used over the last decade in several diseases such as cancers or inflammation.
Elodie Pothin, Dominique Lesuisse, Pierre Lafaye   +2 more
doaj   +2 more sources

Single-Domain Antibodies as Antibody-Drug Conjugates: From Promise to Practice-A Systematic Review. [PDF]

Cancers (Basel)
Simple Summary Antibody–drug conjugates (ADCs) have emerged as a potent cancer therapy by selectively delivering cytotoxic payloads to tumors. However, they face limitations due to acquired resistance and adverse effects.
Medina Pérez VM, Baselga M, Schuhmacher AJ.   +2 more
europepmc   +2 more sources

Single-domain antibodies directed against hemagglutinin and neuraminidase protect against influenza B viruses [PDF]

Nature Communications
Influenza B viruses are antigenically diverse and contribute significantly to the annual influenza burden. Here we report influenza B virus neutralizing single-domain antibodies that target highly conserved regions of the hemagglutinin and neuraminidase.
Arne Matthys, Jan Felix, Joao Paulo Portela Catani, Kenny Roose, Wim Nerinckx, Benthe Van Buyten, Daria Fijalkowska, Nico Callewaert, Savvas N. Savvides, Xavier Saelens   +9 more
doaj   +2 more sources

An Inside Job: Applications of Intracellular Single Domain Antibodies

Biomolecules, 2020
Sera of camelid species contain a special kind of antibody that consists only of heavy chains. The variable antigen binding domain of these heavy chain antibodies can be expressed as a separate entity, called a single domain antibody that is ...
Eline Soetens, Marlies Ballegeer, Xavier Saelens   +2 more
doaj   +2 more sources